Independent learning for medical-device professionals
CommentaryConsulting
LearningMTL-219 · LEARNING BY ROLE

Project Management in Medical-device Development

How to coordinate people, decisions, dependencies and objective evidence so development progresses without losing control.

What you will learn

By the end of this topic, you should be able to explain how project management supports a controlled medical-device lifecycle, build an integrated development plan, manage evidence and technical dependencies, run meaningful decision gates, distinguish schedule status from product readiness and transfer continuing obligations into post-market ownership.

01

The project manager's role

A medical-device project manager does more than track actions, budget and dates. The role creates the organisational conditions in which specialists can make sound decisions, produce controlled evidence and expose problems early enough to act.

Integrate the work

Connect product, regulatory, clinical, engineering, quality, risk, supplier and manufacturing plans around real dependencies.

Make readiness visible

Show whether required decisions, inputs, configurations and evidence are mature—not merely whether activities are reported complete.

Protect decision quality

Ensure reviews include the necessary information, competent participants, explicit outcomes and controlled follow-up.

Escalate uncertainty

Make unresolved assumptions, safety concerns, resource gaps and evidence risk visible before they become late surprises.

Coordinate accountability; do not absorb it

The project manager owns integration and transparent governance. Competent functions remain accountable for clinical, regulatory, risk, quality and technical conclusions, while authorised management retains release and business decisions.

See MTL-218 — Product Management in Medical-device Development for the complementary role of defining and maintaining product intent.

02

Build one integrated development plan

A schedule assembled from independent departmental dates is not an integrated plan. Medical-device development requires explicit connections between the evolving product definition and the evidence needed to support it.

  • Define lifecycle stages, work products, reviews, verification, validation, transfer and release activities.
  • Identify accountable owners, contributors, approvers and interfaces for each work product.
  • Connect regulatory, clinical, risk, usability, cybersecurity and quality activities to engineering decisions.
  • Show supplier deliverables, lead times, controls, reviews and acceptance dependencies.
  • Plan representative units, configurations, fixtures, laboratories, equipment, data and test environments.
  • Include technical-documentation, submission, manufacturing, training, service and launch readiness.
  • Maintain the plan as knowledge, scope, risk and regulatory strategy change.

The development plan should be controlled but usable. It may reference detailed workstream plans, provided the interfaces and governing baseline remain clear. Planning is a lifecycle activity, not a document approved once at project start.

03

Manage dependencies, assumptions and baselines

The most damaging project delays often begin as invisible dependencies: validation planned before user needs are stable, formal testing before the product configuration is defined, or production equipment ordered before critical design decisions are resolved.

Product intentPurpose, users, claims, markets and configurations
Design inputsApproved requirements and risk-control needs
ArchitectureAllocation, interfaces, states and constraints
Design baselineControlled outputs and representative product
EvidenceVerification, validation and regulatory conclusions
ReleaseTransferred, approved and supportable configuration

Track assumptions separately from confirmed facts. Give each important assumption an owner, validation method and decision date. If the project schedule depends on an unconfirmed classification, supplier capability, clinical route or technical performance, the resulting schedule range should remain visible.

A baseline is more than a date. It identifies the approved set of requirements, risks, architecture, outputs or evidence against which subsequent work and change are assessed.

04

Use decision gates to assess readiness

A useful gate decides whether the project has sufficient maturity and controlled uncertainty to commit to the next stage. It is not a ceremonial meeting or a presentation of percentage-complete metrics.

  • Define required inputs and decision criteria before the review.
  • Confirm that reviewers receive the controlled material early enough to assess it.
  • Include the functions competent to evaluate product, safety, regulatory, technical and commercial readiness.
  • Separate evidence, assumptions, open actions and management judgement.
  • Record the decision, rationale, conditions, dissenting concerns, actions and accountable owners.
  • Allow proceed, conditional proceed, repeat, redirect, pause or stop outcomes.
  • Control changes to the baseline and commitments created by the decision.
Green schedule status does not mean the product is ready

A project may be on time while requirements remain ambiguous, risk controls lack evidence or the tested configuration is not releasable. Readiness measures the state of the product and its evidence.

05

Contribution across the lifecycle

Project-management emphasis changes as the product matures, but integration and evidence control continue throughout.

1

Initiation and definition

Confirm the product intent, legal manufacturer, markets, development scope, governance, capabilities, assumptions and major uncertainties before committing to a delivery baseline.

Typical evidence: Project charter, scope, responsibility model, initial regulatory strategy, assumptions and high-level development plan.
2

Integrated planning

Connect design, risk, usability, clinical, software, hardware, cybersecurity, verification, suppliers, manufacturing and regulatory work into one dependency-aware plan.

Typical evidence: Controlled development plan, workstream plans, interfaces, milestones, resources, dependencies and review schedule.
3

Requirements and architecture

Create the conditions for teams to approve complete inputs, resolve interfaces, allocate requirements and establish a reviewable architecture before detailed implementation accelerates.

Typical evidence: Baseline criteria, review records, interface actions, traceability status and approved unresolved-item plan.
4

Implementation and control

Coordinate controlled design outputs, supplier work, reviews, configuration, anomalies and changes while preserving the relationship to requirements and risk controls.

Typical evidence: Design-review records, controlled baselines, decision log, supplier status, issue records and change assessments.
5

Verification and validation

Ensure plans, protocols, samples, configurations, facilities, equipment, acceptance criteria and prerequisites are ready before formal evidence-generating work begins.

Typical evidence: Readiness reviews, approved protocols, configuration records, results, deviations, reports and traceability.
6

Transfer and release

Integrate production, suppliers, process validation, training, documentation, regulatory clearance and release evidence into a genuine readiness decision.

Typical evidence: Transfer plan, manufacturing-readiness review, submission status, release checklist and authorised approvals.
7

Lifecycle and closure

Transfer ownership of open commitments, surveillance, maintenance, security, service, supplier and evidence obligations rather than declaring completion at launch.

Typical evidence: Lifecycle handover, open-action ownership, support baseline, lessons learned and closure record.

See MTL-101 — The Medical-device Development Lifecycle for the complete lifecycle context.

06

Plan evidence, not merely activity

Formal verification and validation are frequent sources of late delay because the project planned test execution but not the prerequisites for valid evidence.

Approved inputs

Requirements, risk controls, claims and acceptance criteria must be sufficiently complete and reviewed.

Representative configuration

Samples, software, accessories, labelling, production status and environments must match the evidence purpose.

Capable method

Protocols, equipment, fixtures, laboratories, operators, data handling and statistical rationale must be ready.

Controlled outcome

Results, deviations, anomalies, failures, changes and conclusions must remain traceable and reviewable.

Reserve time for protocol review, sample manufacture, conditioning, laboratory booking, equipment qualification, investigation, corrective work, justified regression and report approval. Assuming every test passes first time is not a credible project baseline.

See MTL-106 — Verification and Validation for the underlying evidence model.

07

Suppliers, change and escalation

Outsourcing work does not outsource project dependencies or manufacturer responsibility. Supplier plans must connect to the same requirements, risks, interfaces, configuration and evidence system as internal work.

  • Define deliverables, acceptance criteria, records, reviews, access rights and change notification in agreements.
  • Include supplier lead times, dependencies, quality controls and evidence in the integrated plan.
  • Escalate capability, access, intellectual-property or continuity concerns before dependency becomes lock-in.
  • Assess every proposed change for effects on requirements, risks, interfaces, evidence, submissions and released product.
  • Retain the original result and rationale when a failure, deviation or project decision causes rework.
  • Use impact assessment to define regression and revalidation—not schedule pressure alone.

Project escalation should describe the decision needed, available evidence, uncertainty, consequences, options, recommendation and latest responsible decision date. Escalating only “red status” transfers the problem without enabling a decision.

08

Common misconceptions

“Quality owns the documentation.”

Quality defines and assures the system, but every function owns the accuracy, completeness and control of the evidence it creates.

“Agile development removes the need for a development plan.”

No. Iteration can sit within controlled planning, requirements, risk, configuration, review and evidence processes.

“Testing is a late project phase.”

Test strategy, methods, samples, configurations and acceptance criteria depend on early requirements, architecture and risk decisions.

“The critical path is only the longest technical sequence.”

Regulatory questions, clinical evidence, suppliers, sample availability, laboratories, process validation and approvals may control the real path.

“Launch closes the project.”

Open commitments, surveillance, service, maintenance, cybersecurity and supplier obligations require explicit lifecycle ownership.

09

Project manager's readiness dashboard

  1. Is the intended purpose, scope, market and regulatory strategy controlled?
  2. Are responsibilities, interfaces and decision rights explicit?
  3. Are the major assumptions and unresolved decisions visible and owned?
  4. Do requirements, architecture, risk controls and evidence remain connected?
  5. Are suppliers and external laboratories integrated into the plan?
  6. Are formal-test prerequisites and representative configurations genuinely ready?
  7. Are failures, deviations, changes and regression needs controlled?
  8. Can the next gate make a decision from evidence rather than optimism?
  9. Are transfer, release and continuing lifecycle obligations funded and owned?
10

Authoritative starting points

Project structures and terminology vary between organisations. Apply the organisation's approved quality processes and ensure that plans, reviews, records and decisions address the particular device, markets, risks, suppliers and lifecycle model.